共 20 条
[6]
Safety, tolerability, and antibody response of active Aβ immunotherapy with CAD106 in patients with Alzheimer’s disease: randomised, double-blind, placebo-controlled, first-in-human study[J] . Bengt Winblad,Niels Andreasen,Lennart Minthon,Annette Floesser,Georges Imbert,Thomas Dumortier,R Paul Maguire,Kaj Blennow,Joens Lundmark,Matthias Staufenbiel,Jean-Marc Orgogozo,Ana Graf.Lancet Neurology . 2012 (7)
[7]
Randomized, Double-Blind, Parallel-Group, 48-Week Study for Efficacy and Safety of a Higher-Dose Rivastigmine Patch (15 vs. 10 cm) in Alzheimer’s Disease[J] . Cummings, Jeffrey,Froelich, Lutz,Black, Sandra E,Bakchine, Serge,Bellelli, Giuseppe,Molinuevo, José L,Kressig, Reto W,Downs, Pamela,Caputo, Angelika,Strohmaier, Christine.Dementia and Geriatric Cognitive Disorders . 2012 (5)
[8]
Efficacy and Tolerability of a Once Daily Formulation of Ginkgo biloba Extract EGb 761? in Alzheimer’s Disease and Vascular Dementia: Results from a Randomised Controlled Trial[J] . R. Ihl,M. Tribanek,N. Bachinskaya.Pharmacopsychiatry . 2012 (02)
[9]
Memantine in Everyday Clinical Practice: A Comparison of Studies in Germany and Greece[J] . F?rstl, H,Stamouli, S S,Janetzky, W,Galanopoulos, A,Karageorgiou, C,Tzanakaki, M.Dementia and Geriatric Cognitive Disorders . 2012 (4)
[10]
Memantine and Brain Atrophy in Alzheimer’s Disease: A 1-Year Randomized Controlled Trial[J] . David Wilkinson,Nick C. Fox,Frederik Barkhof,Ravinder Phul,Ole Lemming,Philip Scheltens.Journal of Alzheimer’s Disease . 2011 (2)